Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

4/13/22 4:05:00 PM ET

Industrial Specialties

Industrials

Get the next $ZY alert in real time by email

EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results.

A webcast of the conference call can be accessed at https://investors.zymergen.com/.

About Zymergen

Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world.

Investor Contact

[email protected]

Get the next $ZY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZY

Date	Price Target	Rating	Analyst
3/2/2022		Market Perform	Cowen
1/12/2022	$6.50	Reduce → Hold	HSBC Securities
10/15/2021		Market Perform	Cowen
9/27/2021	$12.00	Neutral → Underweight	JP Morgan
8/31/2021	$56.00 → $13.00	Buy → Neutral	UBS
8/4/2021	$43.00 → $7.00	Buy → Underperform	BofA Securities
8/4/2021		Outperform → Market Perform	Cowen & Co.
8/4/2021	$55.00 → $12.00	Buy → Neutral	Goldman Sachs

More analyst ratings

$ZY
Press Releases

Fastest customizable press release news feed in the world

Ginkgo Bioworks Completes Acquisition of Zymergen
BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t
10/19/22 9:08:00 AM ET
$DNA
$ZY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Industrial Specialties
Industrials
Ginkgo to Acquire Zymergen
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac
7/25/22 7:01:00 AM ET
$DNA
$ZY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Industrial Specialties
Industrials
Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform
EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l
7/14/22 4:56:39 PM ET
$ZY
Industrial Specialties
Industrials

Ginkgo to Acquire Zymergen
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac
7/25/22 7:01:00 AM ET
$DNA
$ZY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Industrial Specialties
Industrials
Zymergen Reports Preliminary First Quarter 2022 Financial Results
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r
5/12/22 4:05:00 PM ET
$ZY
Industrial Specialties
Industrials
Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022
EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest
4/13/22 4:05:00 PM ET
$ZY
Industrial Specialties
Industrials

Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

Chat with this insight

Recent Analyst Ratings for
$ZY

$ZY
Press Releases

Fastest customizable press release news feed in the world

Ginkgo Bioworks Completes Acquisition of Zymergen

Ginkgo to Acquire Zymergen

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

$ZY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares

SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company

SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company

$ZY
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cowen resumed coverage on Zymergen

Zymergen upgraded by HSBC Securities with a new price target

Cowen resumed coverage on Zymergen

$ZY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

SEC Form SC 13G filed by Zymergen Inc.

SEC Form SC 13G filed by Zymergen Inc.

$ZY
Financials

Live finance-specific insights

Ginkgo to Acquire Zymergen

Zymergen Reports Preliminary First Quarter 2022 Financial Results